SKELETAL CELL THERAPY SUPPORT

SCTSInactive

KBO/BCE: BE 0841.570.812

Inactive; last annual accounts for fiscal year 2021.

Watch Print / PDF

Signals

1 signal. The signal on the left, the evidence on the right.

○neutral

Latest accounts filed on time

The financial year that closed on 30-06-2021 was due by 31-01-2022 and was filed on 19-01-2022, 12 days ahead of the deadline.

NBB · 9 filings

Deviation from the deadline

2021

12 d early

2019

46 d early

2018

40 d early

2017

43 d early

2016

55 d early

2015

32 d early

2014

32 d early

← before the deadline after the deadline →

Checked, nothing found (1)

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2021, full schema

Turnover

€464k

EBIT margin

-315.1%

Net result

€-1.37M

Working capital

€-534k

Balance-sheet composition

Assets €7.35M

94.2%

Fixed assets €6.92M

Current assets €430k

Equity and liabilities €7.35M

86.2%

13.8%

Equity €6.34M

Debt €1.02M

Debt finances 13.8% of the balance-sheet total.

Key figures and ratios

2021 value

EBITDA

€-626k

Cash flow

€-538k

Current ratio

0.45

Debt to equity

0.01

ROE

-21.7%

ROA

-18.7%

Interest coverage

-6.31

Debt ≤ 1 year

€964k

Debt > 1 year

€54k

Income taxes

€-19k

Filed annual accounts As filed with the NBB · 2021 · 27 lines

Balance sheet Code2021

Assets

Total assets20/58€7.35M

Fixed assets21/28€6.92M

Tangible fixed assets22/27€6.64M

Financial fixed assets28€281k

Current assets29/58€430k

Amounts receivable within one year40/41€136k

Current investments50/53€55k

Cash at bank and in hand54/58€215k

Equity and liabilities

Total equity and liabilities10/49€7.35M

Equity10/15€6.34M

Contributions10/11€5.58M

Reserves13€19k

Profit (loss) carried forward14€-1.09M

Amounts payable17/49€1.02M

Amounts payable after more than one year17€54k

Amounts payable within one year42/48€964k

Trade debts44€811k

Income statement Code2021

Turnover70€464k

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€837k

Operating profit (loss)9901€-1.46M

Recurring financial income75€190k

Recurring financial charges65€121k

Debt charges650€99k

Profit (loss) for the period before taxes9903€-1.39M

Income taxes67/77€-19k

Profit (loss) for the period9904€-1.37M

Profit (loss) for the period to be appropriated9905€-1.37M

Download as CSV

Timeline · acts, filings and financial milestones

All 10Gazette 1Filings 9

2022

19-01

NBB filing Annual accounts filed

fiscal year 2021 · full schema

2021

09-11

State Gazette act Merger · Accounting effect

Power of attorney

2020

15-06

NBB filing Annual accounts filed

fiscal year 2019 · full schema

2019

21-06

NBB filing Annual accounts filed

fiscal year 2018 · full schema

2018

18-06

NBB filing Annual accounts filed

fiscal year 2017 · full schema

2017

06-06

NBB filing Annual accounts filed

fiscal year 2016 · full schema

2016

29-06

NBB filing Annual accounts filed

fiscal year 2015 · full schema

2015

29-06

NBB filing Annual accounts filed

fiscal year 2014 · full schema

2014

27-06

NBB filing Annual accounts filed

fiscal year 2013 · full schema

2013

26-06

NBB filing Annual accounts filed

fiscal year 2012 · full schema

State Gazette actNBB filing

Structure & network

Ownership & control

1 parent company

Control over this companyparent company per the LEI register1

BioSenic

Tubize

controls

SKELETAL CELL THERAPY SUPPORT, EN ABREGE : SCTSBE 0841.570.812

Acquisitions and mergers

1 transaction

Taken over by:Catalent Gosselies SA

BE 0840.843.708proposal · State Gazette act of 09-11-2021

Recognitions · licences · registrations

Legal Entity Identifier

549300AMMNSV1RPRXX43

no longer live in the LEI register